Core Viewpoint - Jiangzhong Pharmaceutical Co., Ltd. is implementing a buyback and cancellation of certain restricted stocks as part of its 2021 stock incentive plan, which aims to enhance employee motivation and ensure sustainable development [1][5][10]. Summary by Sections Legal Framework - The legal opinion is based on the Company Law, Securities Law, and relevant regulations regarding stock incentive management [2][3]. - The law firm confirms that the company has provided all necessary and truthful documentation for the issuance of this legal opinion [3]. Buyback Authorization - The buyback plan has been approved by the company's board and is in compliance with the relevant legal requirements [4][10]. - The company aims to establish a long-term incentive mechanism to motivate core employees and does not harm the interests of the company or its shareholders [5][10]. Buyback Details - The buyback is due to certain employees no longer meeting the incentive conditions, resulting in the cancellation of 42,733 shares, which is 0.0067% of the total share capital [11]. - The adjusted buyback price is set at 2.0998 yuan per share, based on previous cash dividends [12][13]. - The total amount for the buyback is 89,730.75 yuan, sourced from the company's own funds [12][13]. Conclusion - The legal opinion concludes that the company has fulfilled the necessary legal procedures for the buyback and cancellation of shares, and further actions will be taken in accordance with relevant regulations [13].

证券代码：600750 证券简称：江中药业 公告编号：2025-043 江中药业股份有限公司 关于 2021 年限制性股票激励计划回购注销部分 限制性股票及调整回购价格的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●根据 2021 年第二次临时股东大会授权，本次回购注销部分限制性股票属 授权董事会决策事项，无须提交公司股东大会进行审议； ●本次回购注销的限制性股票数量：合计 42,733 股，涉及人数 9 人； ●本次回购限制性股票的价格：42,733 股限制性股票的回购价格为 2.0998 元/股，回购金额共计 89,730.75 元，均为公司自有资金。 江中药业股份有限公司（以下简称"公司"）于 2025 年 8 月 20 日召开第十 届董事会第七次会议和第十届监事会第七次会议，审议通过了《关于回购注销 部分激励对象已获授但尚未解除限售的限制性股票及调整回购价格的议案》。鉴 于 1 名激励对象因辞职已不符合激励条件，8 名激励对象年度个人绩效考核不 符合第三个解除限售期全部解锁要求，根据《江 ...

江中药业股份有限公司 关于回购注销部分限制性股票通知债权人的公告 证券代码：600750 证券简称：江中药业 公告编号：2025-044 江中药业股份有限公司（以下简称"公司"）于 2025 年 8 月 20 日召开第十 届董事会第七次会议审议通过了《关于回购注销部分激励对象已获授但尚未解 除限售的限制性股票及调整回购价格的议案》。1 名激励对象因辞职已不符合激 励条件，8 名激励对象年度个人绩效考核不符合第三个解除限售期全部解锁要 求，根据《江中药业股份有限公司 2021 年限制性股票激励计划（2022 年 11 月 修订稿）》《上市公司股权激励管理办法》等相关规定，公司对 9 名激励对象已 获授但尚未解除限售的限制性股票共计 42,733 股进行回购注销（具体内容详见 公司同日披露的《关于 2021 年限制性股票激励计划回购注销部分限制性股票及 调整回购价格的公告》（公告编号：2025-043）。本次回购注销完成后公司总股 本减少 42,733 股，由 634,996,022 股减少至 634,953,289 股，注册资本减少 后履行工商变更登记等相关程序。根据公司于 2021 年 11 月 8 日召开的 ...

Core Viewpoint - Jiangzhong Pharmaceutical Co., Ltd. reported a net profit of 522.34 million yuan for the first half of 2025, reflecting a year-on-year increase of 5.80% despite a decline in revenue [2][3][9] Financial Performance - Total revenue for the first half of 2025 was 2.14 billion yuan, down 5.79% from the previous year [2][3] - The total profit for the period was 703.24 million yuan, an increase of 12.01% compared to the same period last year [2][3] - The company's net assets reached 3.95 billion yuan, up 2.15% year-on-year [3] Business Segments - The OTC (over-the-counter) segment saw a revenue decline of 10.14%, attributed to changes in terminal demand [14] - The health consumer products segment achieved a revenue growth of 17.35%, focusing on self-researched products [14] - The prescription drug segment reported a revenue increase of 7.44%, emphasizing compliance and academic marketing [15] Industry Context - The pharmaceutical manufacturing industry experienced a PPI decline of 1.5% in the first half of 2025, with total revenue down 1.2% year-on-year [4][5] - National policies are aimed at enhancing medical insurance coverage and promoting high-quality development in the pharmaceutical sector [5][6] - The government is focusing on the development of traditional Chinese medicine, with initiatives to improve quality and promote innovation [8] Strategic Initiatives - The company is committed to brand-driven and innovation-driven growth, with plans to enhance its product matrix in key categories [18] - Jiangzhong Pharmaceutical is actively pursuing mergers and acquisitions to expand its product offerings and market presence [18] - The company is investing in digital transformation and smart manufacturing to improve operational efficiency and product quality [16][17]

Core Viewpoint - Jiangzhong Pharmaceutical Co., Ltd. reported a decrease in revenue and a profit increase in its 2025 semi-annual report, highlighting strategic adjustments and business performance across its OTC, health consumer products, and prescription drug segments [1][8]. Financial Summary - Total assets increased to approximately 6.64 billion RMB, a 1.96% increase from the previous year [2]. - Operating revenue for the period was approximately 2.14 billion RMB, a decrease of 5.79% compared to the previous year [2]. - Total profit reached approximately 703.24 million RMB, reflecting a 12.01% increase year-on-year [2]. Business Segment Performance OTC Business - The OTC segment generated revenue of 1.55 billion RMB, a decline of 10.14% year-on-year, attributed to changes in terminal demand [8][9]. - The company focused on strengthening its brand presence and expanding product categories, particularly in gastrointestinal and throat health products [8]. Health Consumer Products - Revenue from health consumer products reached approximately 228 million RMB, marking a 17.35% increase year-on-year [9]. - The company emphasized self-research and development, enhancing its e-commerce capabilities and exploring new sales models [9]. Prescription Drug Business - The prescription drug segment achieved revenue of approximately 360 million RMB, a 7.44% increase year-on-year [10]. - The company adapted to industry policy changes and focused on academic marketing and compliance in both hospital and outpatient markets [10]. Strategic Initiatives - The company is committed to innovation and brand-driven growth, focusing on high-quality development and expanding its product matrix [11][13]. - Ongoing investments in R&D led to the authorization of 11 patents in traditional Chinese medicine [11][14]. - The company aims to enhance digital transformation across its operations, improving marketing and R&D efficiency [12][14]. Future Plans - The company plans to strengthen its core product categories and explore external mergers and acquisitions to enhance its market position [13][14]. - Emphasis will be placed on developing innovative products and optimizing production processes to improve efficiency and sustainability [14].

人民财讯8月21日电，江中药业（600750）8月21日晚间披露2025年半年度报告，上半年实现营业收入 21.41亿元，同比下降5.79%；归母净利润5.22亿元，同比增长5.80%；基本每股收益0.82元。公司拟向分 红派息股权登记日登记在册的股东每10股分配现金红利5元(含税)。 ...

证券代码：600750 证券简称：江中药业 公告编号：2025-044 江中药业股份有限公司 关于回购注销部分限制性股票通知债权人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、通知债权人的原由 江中药业股份有限公司（以下简称"公司"）于 2025 年 8 月 20 日召开第十 届董事会第七次会议审议通过了《关于回购注销部分激励对象已获授但尚未解 除限售的限制性股票及调整回购价格的议案》。1 名激励对象因辞职已不符合激 励条件，8 名激励对象年度个人绩效考核不符合第三个解除限售期全部解锁要 求，根据《江中药业股份有限公司 2021 年限制性股票激励计划（2022 年 11 月 修订稿）》《上市公司股权激励管理办法》等相关规定，公司对 9 名激励对象已 获授但尚未解除限售的限制性股票共计 42,733 股进行回购注销（具体内容详见 公司同日披露的《关于 2021 年限制性股票激励计划回购注销部分限制性股票及 调整回购价格的公告》（公告编号：2025-043）。本次回购注销完成后公司总股 本减少 42,733 股 ...

证券代码：600750 证券简称：江中药业 公告编号：2025-043 江中药业股份有限公司 关于 2021 年限制性股票激励计划回购注销部分 限制性股票及调整回购价格的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●根据 2021 年第二次临时股东大会授权，本次回购注销部分限制性股票属 授权董事会决策事项，无须提交公司股东大会进行审议； ●本次回购注销的限制性股票数量：合计 42,733 股，涉及人数 9 人； ●本次回购限制性股票的价格：42,733 股限制性股票的回购价格为 2.0998 元/股，回购金额共计 89,730.75 元，均为公司自有资金。 江中药业股份有限公司（以下简称"公司"）于 2025 年 8 月 20 日召开第十 届董事会第七次会议和第十届监事会第七次会议，审议通过了《关于回购注销 部分激励对象已获授但尚未解除限售的限制性股票及调整回购价格的议案》。鉴 于 1 名激励对象因辞职已不符合激励条件，8 名激励对象年度个人绩效考核不 符合第三个解除限售期全部解锁要求，根据《江 ...

国浩律师（上海）事务所 关 于 江中药业股份有限公司 2021 年限制性股票激励计划 回购注销部分限制性股票事宜 的 法律意见书 上海市静安区山西北路 99 号苏河湾中心 25-28 楼 邮编：200085 25-28/F, Suhe Centre, 99 North Shanxi Road, Jing'an District, Shanghai, China 电话/Tel: +86 21 52341668 传真/Fax: +86 21 52341670 网址/Website: http://www.grandall.com.cn 2025 年 8 月 | 释 义 | | | 2 | | --- | --- | --- | --- | | 第一节 | | 律师声明事项 | 5 | | 第二节 | 正文 | | 6 | | | | 一、本次回购注销的批准与授权 | 6 | | | | 二、本次回购注销的主要内容 | 10 | | 三、结论意见 | | | 13 | 释 义 以下词语如无特殊说明，在本文中具有如下含义： | 江中药业、本公司、公司 | 指 | 江中药业股份有限公司 | | --- | --- | ...

格隆汇8月21日丨江中药业(600750.SH)公布2025年半年度报告，报告期实现营业收入21.41亿元，同比下 降5.79%；归属于上市公司股东的净利润5.22亿元，同比增长5.80%；归属于上市公司股东的扣除非经常 性损益的净利润4.82亿元，同比增长2.31%；基本每股收益0.82元。拟每10股分配现金红利5元（含 税）。 ...